2 unloved penny stocks I’m considering buying today!

These penny stocks may have fallen out of favour with UK investors, but I think they could be too cheap to miss following share price falls.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Man smiling and working on laptop

Image source: Getty images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’m searching for great penny stocks to buy following heavy share price weakness. Here are two I think are highly attractive at current prices.

Medical marvel

Medical technology business Polarean Imaging (LSE:POLX) has passed some significant milestones in recent months.

Its landmark XENOVIEW product — which allows MRI scans to give a more complete picture of a patient’s lung health — was signed off by the US Food and Drug Administration (FDA) at the end of 2022. Then in May, the first clinical scan took place at an Ohio hospital using the technology. This followed the company’s maiden sale a month earlier.

So what’s gone wrong with the Polarean share price? As is often the case with penny stocks, it’s money.

The business had a healthy $16m of cash on its balance sheet at the end of last year. But in February, it announced that “the company will need additional cash resources to achieve the 24 month commercial targets and to pursue the development of the next indications and their approvals, and advanced R&D for future products.

A dip-buying opportunity

Chart showing forecast growth in the chronic obstructive pulmonary disease (COPD) treatment market Forecast (In US Dollars)
Predicted growth in the global chronic obstructive pulmonary disease (COPD) treatment market (in US dollars). Source: Precedence Research

Tapping shareholders for cash is one option the business is exploring to plug the funding gap. Yet given recent share price weakness, I’m still considering adding some Polarean shares to my portfolio.

City analysts expect Polarean’s sales to more than double from around $3m this year to $8m in 2024. This is possibly no surprise given the advantages its technologies provide for both medical personnel and patients.

The company’s technology not only provides clearer images, but they can be taken without the use of harmful radiation and don’t require invasive procedures. As the number of people suffering lung-related problems explodes, XENOVIEW has huge growth potential.

The number of people seeking treatment for chronic obstructive pulmonary disease (COPD) alone is tipped to soar over the next decade, as the graph above shows. Soaring cases of asthma, cancer and other conditions also mean demand for Polarean’s expertise could grow strongly.

A top dividend stock

Making a second income from penny stocks can be a difficult task. Usually, any surplus cash these growth-oriented shares make is ploughed back into the business rather than paid out in dividends.

Property stock Alternative Income REIT (LSE:AIRE) is one small-cap share that could provide a passive income however. Under real estate investment rules its required to distribute at least 90% of annual rental profits out by way of dividends.

This is why the firm offers up a huge 8.2% forward dividend yield. That’s more than double a corresponding 3.8% reading for FTSE 100 shares.

Alternative Income invests in a diverse range of real estate assets. This means that, while it can still theoretically struggle to collect rents during downturns, the risk is much reduced. The firm’s portfolio includes hotels, gyms, logistics hubs and care homes.

Encouragingly, 96% of the rental income it receives is inflation linked. This makes it an especially attractive penny stock to own in this period of rampant price rises.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Person holding magnifying glass over important document, reading the small print
Investing Articles

Just released: our top 3 small-cap stocks to consider buying in October [PREMIUM PICKS]

Small-cap shares tend to be more volatile than larger companies, so we suggest investors should look to build up a…

Read more »

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »